Efficacy and safety of Abraxane in treatment of progressive and recurrent non-small cell lung cancer patients: A retrospective clinical study

Thoracic Cancer

Volumn 3, Issue 4, 2012, Pages 341-347

  Yuan, Dong mei ^a   Lv, Yan ling ^b   Yao, Yan wen ^a   Miao, Xiao hui ^a   Wang, Qian ^a   Xiao, Xin wu ^a   Yin, Jie ^a   Shi, Yi ^a   Shi, Mei qi ^c   Zhang, Xiu wei ^d   Song, Yong ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c JIANGSU CANCER HOSPITAL   (China)

^d THE AFFILIATED JIANGNING HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Abraxane; Albumin bound paclitaxel; Non small cell lung cancer; Progressive; Recurrent

Indexed keywords

DOCETAXEL; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR;

ADRENAL METASTASIS; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DISEASE CONTROL; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; LEUKOPENIA; LIVER FUNCTION; LIVER METASTASIS; LUNG ADENOCARCINOMA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; MULTIMODAL CHEMOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; PERIPHERAL NEUROPATHY; PLEURA METASTASIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 84868577071     PISSN: 17597706     EISSN: 17597714     Source Type: Journal    
DOI: 10.1111/j.1759-7714.2012.00113.x     Document Type: Article

References (29)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol 1993; 11: 1866-72.
3. Triano LR, Deshpande H, Gettinger SN. Management of patients with advanced non-small cell lung cancer: current and emerging options. Drugs 2010; 70: 167-79.
4. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. IV. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971; 93: 2325-7.
5. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990; 82: 1247-59.
6. Ranson M, Davidson N, Nicolson M etal. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000; 92: 1074-80.
7. Roszkowski K, Pluzanska A, Krzakowski M etal. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naïve patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000; 27: 145-57.
8. Dorr RT. Pharmacology and toxicology of Cremophor EL diluent. Ann Pharmacother 1994; 28 (Suppl.): S11-14.
9. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001; 37: 1590-8.
10. Weiss RB, Donehower RC, Wiernik PH etal. Hypersensitivity reactions from taxol. J Clin Oncol 1990; 8: 1263-8.
11. Kloover JS, den Bakker MA, Gelderblom H, van Meerbeeck JP. Fatal outcome of hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Cancer 2004; 90: 304-5.
12. Hidalgo M, Aylesworth C, Hammond LA etal. Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel. J Clin Oncol 2001; 19: 2493-503.
13. Sharma A, Mayhew E, Straubinger RM. Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumor model. Cancer Res 1993; 53: 5877-81.
14. Sparreboom A, Scripture CD, Trieu V etal. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 2005; 11: 4136-43.
15. Ibrahim NK, Desai N, Legha S etal. Phase I and pharmacokinetic study of ABI-007, a Cremphor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002; 8: 1038-44.
16. Porter PL, Sage EH, Lane TF, Funk SE, Gown AM. Distribution of SPARC in normal and neoplastic human tissue. J Histochem Cytochem 1995; 43: 791-800.
17. Gradishar WJ, Tjulandin S, Davidson N etal. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23: 7794-803.
18. Rizvi NA, Riely GJ, Azzoli CG etal. Phase I/II trial of weekly intravenous 130nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. J Clin Oncol 2008; 26: 639-43.
19. Reynolds C, Barrera D, Jotte R etal. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 2009; 4: 1537-43.
20. Green MR, Manikhas GM, Orlov S etal. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 2006; 17: 1263-8.
21. Shepherd FA, Dancey J, Ramlau R etal. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-103.
22. Kim HS, Lee GW, Kim JH etal. A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer. Lung Cancer 2010; 70: 71-6.
23. Kim ES, Hirsh V, Mok T etal. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomized phase III trial. Lancet 2008; 372: 1809-18.
24. Eisenhauer EA, Therasse P, Boqaerts J etal. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
25. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36.
26. Koukourakis MI, Giatromanolaki A, Brekken RA etal. Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res 2003; 63: 5376-80.
27. Hirsch FR, Dziadziuszko R, Varella-Garcia M, Franklin WA, Gandara DR, Bunn PA Jr. First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay. J Thorac Oncol 2008; 3 (Suppl.): S138-142.
28. Socinski MA, Manikhas GM, Stroyakovsky DL etal. A dose finding study of weekly and every-3-week nab-paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 2010; 5: 852-61.
29. Yamada K, Yamamoto N, Yamada Y, Mukohara T, Minami H, Tamura T. Phase I and pharmacokinetic study of ABI-007, Albumin-bound paclitaxel, administered every 3 weeks in Japanese patients with solid tumors. Jpn J Clin Oncol 2010; 40: 404-11.